Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 239 participants.

Also called NCT04456803

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 239 participants (enrolled count) (from the registry)
Sponsor
Sinomune Pharmaceutical Co., Ltd (from the registry)
Registry
  • NCT NCT04456803
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04456803. Randomized; no masking; primary purpose treatment. Start 2019-05-24 (actual); primary completion 2022-09-13 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
Condition
Hyperphosphatemia
Condition
End Stage Renal Disease
Condition
ESRD
Intervention (Drug)
Ferric citrate tablet
Intervention (Drug)
Sevelamer carbonate tablet
Lead sponsor
Sinomune Pharmaceutical Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct04456803
Content hash
e830bdb708fc74d7deaf38669827d87eb432f3bd1ec7d6ca025dd5e00e5ca327